Emory/Atlanta Center for AIDS Research
埃默里/亚特兰大艾滋病研究中心
基本信息
- 批准号:8039325
- 负责人:
- 金额:$ 3.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-30 至 2012-07-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS VaccinesAIDS clinical trial groupAIDS vaccine developmentAIDS/HIV problemAcquired Immunodeficiency SyndromeAcuteAffectAffinityAfricanAgeAlabamaAnniversaryAntiviral AgentsAreaArgentinaArtsAwarenessBehavior TherapyBehavioralBehavioral ResearchBiologicalBiological AssayBiometryBiotechnologyCaringCenters for Disease Control and Prevention (U.S.)ClinicClinicalClinical ResearchClinical SciencesClinical Trials UnitCollaborationsCommitCommunicationCommunitiesCommunity OutreachComplexCore FacilityCountryDNA/MVA vaccineDendritic CellsDevelopmentDiagnosticEducational process of instructingEducational workshopElectronic MailEnsureEpidemicEquipmentEvidence based interventionExtramural ActivitiesFacultyFamilyFosteringFundingGoalsGrantGroup MeetingsGrowthHIVHIV Vaccine Trials NetworkHIV vaccineHome environmentHuman immunodeficiency virus testImmuneImmune responseImmunologyIndiaIndividualIndustryInfectionInstitutionInterdisciplinary StudyInternationalIntervention StudiesInvestmentsKnowledgeLaboratoriesLaboratory ResearchLeadershipLongevityMeasuresMentored Clinical Scientist Development ProgramMentorsMentorshipMethodologyMethodsMexicoMissionModelingNorth CarolinaOutcomePathogenesisPatientsPennsylvaniaPharmacologic SubstancePhasePreventionPreventive InterventionRecording of previous eventsRecruitment ActivityResearchResearch InfrastructureResearch PersonnelResearch Project GrantsResearch SupportResourcesRiskRoleRwandaScienceScientistSeriesServicesShapesSustainable DevelopmentTechnology TransferTeenagersTestingTherapeutic InterventionTimeTrainingTraining ProgramsTraining and EducationTranslational ResearchTrusteesUnited States National Institutes of HealthUniversitiesVaccinesVisitWomanWorkWritingZambiaantiretroviral therapybasebehavioral/social sciencecareerdesigndrug discoveryemtricitabineevidence baseinnovationinterestmedical schoolsmeetingsmembermultidisciplinarynext generationnoveloutreachpost-doctoral trainingpre-clinicalprogramsskillssocialsymposiumvaccine developmentvirology
项目摘要
Through scientifically rigorous basic, clinical, translational, and behavioral research, the Emory CFAR will develop and disseminate effective preventions and therapeutic interventions for the global AIDS epidemic. The Emory CFAR supports and promotes the National CFAR mission by providing institutional infrastructure and leadership; conducting and implementing strategic and operational planning for HIV
research; funding CFAR science cores that support interdisciplinary research; supporting the recruitment and development of faculty in HIV research; maintaining effective communications and sharing of scientific findings; and promoting interactions of the Emory CFAR with outside institutions and the community.
Since the inception of the Emory CFAR in 1997, HIV research at the University has expanded dramatically. The CFAR has fostered recruitment of over thirty additional faculty and attracted substantially increased institutional support to further facilitate the growth of HIV/AIDS research. Under CFAR leadership, extramural HIV research funding at Emory has grown from $23 million ($7.7 million NIH) in 1996 to over $58
million ($29.9 million NIH) in 2005.
The Emory CFAR will be led by an Executive Committee (composed of the CFAR Directors, Drs. James Curran, Carlos del Rio, and Eric Hunter; the CFAR Associate Directors and Assistant Director) and be advised by the Core Directors, several key HIV/AIDS scientists at Emory, and an external and community advisory board. The Emory CFAR serves over 100 funded HIV/AIDS Investigators. Seven core facilities
have been established to meet the CFAR objectives including Administrative, Developmental, and 5 science cores (Social and Behavioral Science, Clinical Research, Biostatistics, Immunology, and Virology/Drug Discovery). Services provided by these cores are critical in facilitating growth in all aspects of Emory University's five principal HIV/AIDS research domains: Vaccine Development and Testing, HIV Pathogenesis & Drug Discovery, Prevention Science, Clinical & Translational Science, and International Research. The CFAR will foster development of the next generation of HIV/AIDS researchers through training and mentorship of domestic and international investigators.
通过科学严谨的基础、临床、转化和行为研究,埃默里 CFAR 将为全球艾滋病流行开发和传播有效的预防和治疗干预措施。埃默里 CFAR 通过提供机构基础设施和领导力来支持和促进国家 CFAR 使命;制定和实施艾滋病毒战略和业务规划
研究;资助支持跨学科研究的 CFAR 科学核心;支持艾滋病毒研究教师的招聘和发展;保持有效的沟通和分享科学发现;促进埃默里 CFAR 与外部机构和社区的互动。
自 1997 年埃默里 CFAR 成立以来,该大学的艾滋病毒研究急剧扩大。 CFAR 已招募了 30 多名额外的教职人员,并吸引了更多的机构支持,以进一步促进艾滋病毒/艾滋病研究的发展。在 CFAR 的领导下,埃默里大学的校外 HIV 研究经费已从 1996 年的 2300 万美元(NIH 770 万美元)增加到超过 58 美元
2005 年 100 万美元(2990 万美元 NIH)。
埃默里 CFAR 将由执行委员会领导(由 CFAR 董事 James Curran、Carlos del Rio 博士和 Eric Hunter 博士、CFAR 副主任和助理主任组成),并由核心主任、几位关键的 HIV/埃默里大学的艾滋病科学家以及外部和社区咨询委员会。埃默里 CFAR 为 100 多名受资助的艾滋病毒/艾滋病调查人员提供服务。七大核心设施
已建立以满足 CFAR 目标,包括管理、发展和 5 个科学核心(社会和行为科学、临床研究、生物统计学、免疫学和病毒学/药物发现)。这些核心提供的服务对于促进埃默里大学五个主要艾滋病毒/艾滋病研究领域各个方面的发展至关重要:疫苗开发和测试、艾滋病毒发病机制和药物发现、预防科学、临床和转化科学以及国际研究。 CFAR 将通过对国内和国际研究人员的培训和指导,促进下一代艾滋病毒/艾滋病研究人员的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES W. CURRAN其他文献
JAMES W. CURRAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES W. CURRAN', 18)}}的其他基金
Predicting the Effect of Testing For and Treating HIV in Correctional Facilities
预测惩教设施中艾滋病毒检测和治疗的效果
- 批准号:
8134701 - 财政年份:2010
- 资助金额:
$ 3.86万 - 项目类别:
相似海外基金
TUBERCULOSIS PREVENTION IN CHILDREN TWO TO LESS THAN 13 YEARS OF AGE WITH AND WITHOUT HIV
感染和未感染 HIV 的 2 岁至 13 岁以下儿童的结核病预防
- 批准号:
10872953 - 财政年份:2023
- 资助金额:
$ 3.86万 - 项目类别:
Reducing HIV vaccine and prevention hesitancy among sexual and gender minority adolescents
减少性少数和性别少数青少年对艾滋病毒疫苗和预防的犹豫
- 批准号:
10620502 - 财政年份:2023
- 资助金额:
$ 3.86万 - 项目类别:
CoVPN 3008 A Phase 3, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
CoVPN 3008 COVID-19 mRNA 疫苗在 SARS-CoV-2 变异关注地区的 3 期、多中心、随机、功效研究
- 批准号:
10493538 - 财政年份:2022
- 资助金额:
$ 3.86万 - 项目类别:
Effects of SARS-CoV-2 Antiviral Ribonucleoside Analogues on Mitochondrial DNA
SARS-CoV-2 抗病毒核糖核苷类似物对线粒体 DNA 的影响
- 批准号:
10448062 - 财政年份:2022
- 资助金额:
$ 3.86万 - 项目类别:
PHASE I STUDY OF PHARMACOKINETICS, SAFETY AND ACCEPTABILITY OF A SINGLE DOSE OF PRETOMANID ADDED TO AN OPTIMIZED BACKGROUND REGIMEN IN CHILDREN WITH RIFAMPICIN RESISTANT TUBERCULOSIS IMPAACT 2034
对患有利福平耐药结核病儿童的单剂量 Pretomanid 的药代动力学、安全性和可接受性的 I 期研究添加到优化背景方案中的影响 2034
- 批准号:
10679271 - 财政年份:2022
- 资助金额:
$ 3.86万 - 项目类别: